Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation
source: pixabay.com

Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation

Immune-Onc Therapeutics recently received clearance from the FDA to begin trials of IO-202, a treatment for acute myeloid leukemia (AML). This news comes after the cancer immunotherapy company filed an…

Continue Reading Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation

Libtayo Demonstrates Positive Results in the Treatment of Squamous Cell Carcinoma

Libtayo, a product of Regeneron Pharmaceuticals, has shown positive results in the treatment of those with advanced cutaneous squamous cell carcinoma. This data comes from a Phase 2 trial and…

Continue Reading Libtayo Demonstrates Positive Results in the Treatment of Squamous Cell Carcinoma
New Pediatric Certified Duchenne Muscular Dystrophy Care Center in Texas
source: pixabay.com

New Pediatric Certified Duchenne Muscular Dystrophy Care Center in Texas

Parent Project Muscular Dystrophy is a nonprofit that aims to find a cure for Duchenne muscular dystrophy. One of their programs, the Certified Duchenne Care Center Program (CDCCP), has recently…

Continue Reading New Pediatric Certified Duchenne Muscular Dystrophy Care Center in Texas
Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
source: pixabay.com

Arimoclomol Receives the Fast Track Designation for the Treatment of ALS

CytRx Corporation has recently received the Fast Track designation for their ALS treatment, arimoclomol. This status was also given for the treatment of Niemann-Pick disease and sporadic Inclusion Body Myositis…

Continue Reading Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases
source: pixabay.com

Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases

Anavex Life Sciences Corporation has recently announced that they will conduct a clinical trial for their small molecule, ANAVEX®3-71. This therapy is intended to treat neurodegenerative and neurodevelopmental conditions, such…

Continue Reading Study: ANAVEX 3-71 as a Treatment for Neurodegenerative Diseases
Sanfilippo Syndrome Treatment Receives Rare Pediatric Disease Designation
qimono / Pixabay

Sanfilippo Syndrome Treatment Receives Rare Pediatric Disease Designation

Seelos Therapeutics has recently received the Rare Pediatric Disease Designation for their Sanfilippo syndrome treatment, trehalose. This designation is an incentive for companies to make therapies for conditions with an…

Continue Reading Sanfilippo Syndrome Treatment Receives Rare Pediatric Disease Designation

European Commission Grants Conditional Approval for Spinal Muscular Atrophy Treatment

Zolgensma, a gene therapy for spinal muscular atrophy (SMA), has recently been granted conditional approval by the European Commission (EC). This is extremely exciting news for those living with SMA…

Continue Reading European Commission Grants Conditional Approval for Spinal Muscular Atrophy Treatment
Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
source: pixabay.com

Study: EDP-305 for the Treatment of Primary Biliary Cholangitis

Enanta Pharmaceuticals has recently released the results from the second phase of its INTREPID trial, which studied EDP-305 as a treatment for primary biliary cholangitis (PBC). The results were positive,…

Continue Reading Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
New Therapy for ALS and Other Neurodegenerative Diseases
geralt / Pixabay

New Therapy for ALS and Other Neurodegenerative Diseases

ProMIS Neurosciences is a biotechnology company that works specifically with antibody treatments, and they have recently developed intrabodies for the treatment of amyotrophic lateral sclerosis (ALS). This same therapy has…

Continue Reading New Therapy for ALS and Other Neurodegenerative Diseases
Close Menu